Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne Corporation (NASDAQ: TECH) has announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders using its Ella platform. This platform offers high-quality, automated immunoassays with results delivered in 90 minutes using only 25 µL of sample. Under the collaboration, Ella instruments will be provided for clinical trials in India, aiming for regulatory approval as a diagnostic device. Executives highlighted Ella's potential to enhance diagnostics in ophthalmology.

Bio-Techne Corporation (NASDAQ:TECH) announced the successful results of the AmplideX® PCR/CE SMA Plus Kit from a multisite evaluation study. Published in The Journal of Molecular Diagnostics, the kit showed 98.6% accuracy for SMN1 and 97.1% for SMN2 in diagnosing spinal muscular atrophy (SMA), a condition affecting 1 in 6,000 births. The kit facilitates carrier screening and diagnosis in a streamlined manner, critical for timely treatment. The study involved 468 clinical samples across several international laboratories demonstrating high concordance with established diagnostic methods.

Bio-Techne Corporation (NASDAQ: TECH) has announced a quarterly dividend of $0.32 per share for the period ending March 31, 2021. This dividend will be paid on May 28, 2021 to shareholders recorded by May 17, 2021. The company, a global leader in life sciences, reported approximately $739 million in net sales for fiscal 2020 and employs over 2,300 people worldwide. The Board will continue to evaluate future dividends on a quarterly basis.

Bio-Techne Corporation (NASDAQ:TECH) reported strong financial results for Q3 FY2021, with organic revenue growth of 22% to $243.6 million. GAAP EPS increased to $1.12, up from $0.92 last year, while adjusted EPS rose to $1.79 from $1.39. The company achieved a remarkable adjusted operating margin of 40.1%, reflecting effective cost management and higher demand across its segments. Notably, Protein Sciences experienced organic growth of 24%, while Diagnostics and Genomics grew by 17%. Bio-Techne also enhanced its Diagnostics segment through the acquisition of Asuragen.

Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.

908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) announced a collaboration to enhance protein characterization workflows. This partnership combines Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip technology, streamlining the analysis process for biotherapeutics. The integrated solution aims to improve drug development efficiency by providing rapid, high-resolution separation techniques and mass spectrometry identification, catering to the growing biopharmaceutical market.

Bio-Techne Corporation (NASDAQ:TECH) announced the launch of DNAscope Assays, expanding their Advanced Cell Diagnostics RNAscope technology. This new chromogenic DNA in situ hybridization (ISH) technology allows for single-cell resolution to visualize DNA aberrations in FFPE tissues using standard bright-field microscopes. DNAscope provides advantages over traditional FISH techniques, offering precise detection of small genomic regions. Kim Kelderman, President of Diagnostics and Genomics Segment, stated that this launch strengthens their position in spatial genomic analysis, enhancing multi-omic capabilities for faster decision-making.

Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its Pharma Assay Services to Professional Assay Services, aimed at enhancing accessibility for global academic and clinical institutions. The updated services include in situ hybridization (ISH) gene expression analysis, tissue procurement, and custom assay development. Supported by a team of experts, these services comply with Good Clinical Laboratory Practices (GCLP). Kim Kelderman, President of Diagnostics and Genomics, emphasized the commitment to facilitate faster drug development timelines while maintaining cost efficiency.